The Evolution of Psychedelic Research: From The Lancet to US Policy

A United States president has signed an executive order designed to dramatically accelerate access to new medical research and treatments based on psychedelic drugs. This policy shift represents a significant change in the regulatory approach to substances that were previously subject to strict prohibitions.

The development was highlighted in a May 16, 2026, editorial published by The Lancet titled Psychedelics: after the renaissance. In the piece, the medical journal examined the trajectory of psychedelic research and the evolving landscape of mental health treatment.

A Shift in Medical Research Barriers

The current movement toward accelerated access contrasts sharply with the medical and legal environment of two decades ago. In 2006, The Lancet published an editorial calling for the revival of research into the use of psychedelics for treating mental health conditions.

At that time, the journal identified systemic obstacles that prevented scientists from exploring the therapeutic potential of these drugs. The 2006 editorial noted the restrictive nature of global drug policies:

the blanket ban on psychedelic drugs enforced in many countries continues to hinder safe and controlled investigation, in a medical environment, of their potential benefits

The Lancet, 2006

The primary concern in 2006 was that these blanket bans created a barrier to conducting safe and controlled investigation within professional medical environments, thereby stalling the discovery of potential benefits for patients with mental health disorders.

From Prohibition to Acceleration

The transition from the constraints described in 2006 to the current executive order indicates a pivot in how the U.S. Government views the intersection of psychedelic substances and medicine. While the 2006 perspective focused on the hindrance caused by bans, the 2026 directive specifically aims to accelerate the availability of both research and the resulting treatments.

This shift suggests a growing institutional recognition of the need for medical frameworks that allow for the investigation of psychedelic-based therapies. By removing or reducing the barriers that once hindered controlled studies, the executive order seeks to expedite the development of new options for mental health care.

The Lancet’s May 16, 2026, editorial suggests that the medical community has entered a new phase, moving beyond the initial revival of interest—or the renaissance—and into a period of active implementation and expanded access.